Pancreatic Cancer Research

ResearcherOrcidActive in the last 2 years

Nikolaos A. Chatzizacharias

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-4864-189X; OpenAlex author ID A5062363812. Sources: OpenAlex.

Their work

Papers
27 (first author 2, last author 14)
Trials
0
Grants
0
Labs led
2
Collaborators
33
Papers, trials and grants by year

2020: 3 papers · 2021: 2 papers · 2022: 1 paper · 2023: 4 papers · 2024: 4 papers · 2025: 3 papers · 2026: 10 papers

Papers 27

  1. Colonization of bile with gammaproteobacteria is associated with reduced survival after surgery for pancreatic cancer in patients receiving gemcitabine-based a… Co-author DOI 10.1016/j.ejso.2026.111396↗
  2. Effect of duration of neoadjuvant therapy on pancreatic cancer outcomes: a systematic review and meta-analysis. Co-author DOI 10.1016/j.hpb.2025.12.018↗
  3. Intention to treat outcomes following management of locally advanced pancreatic ductal adenocarcinoma with curative intent: single centre cohort study. Last author DOI 10.1016/j.hpb.2026.06.008↗
  4. R0 Resection improves survival after multivisceral resection for pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.isci.2026.117352↗
  5. Response to 'Towards an individualized strategy in perioperative chemotherapy for pancreatic cancer'. Co-author DOI 10.1038/s41416-025-03294-w↗
  6. Temporary Mesocaval Shunt: A Surgical Strategy to Facilitate Pancreatic Cancer Resection With Complex Vascular Involvement. Last author DOI 10.1111/ans.70977↗
  7. Neoadjuvant Chemoradiotherapy Versus Chemotherapy in Patients with Pancreatic Ductal Adenocarcinoma: A Systematic Review and Meta-analysis of Randomised Contro… Last author DOI 10.1245/s10434-026-20319-7↗
  8. ASO Author Reflections: It is Time to Define an Optimal Duration of Neoadjuvant Treatment in Patients with Pancreatic Ductal Adenocarcinoma. Last author DOI 10.1245/s10434-026-20436-3↗
  9. ASO Visual Abstract: Neoadjuvant Chemoradiotherapy versus Chemotherapy in Patients with Pancreatic Ductal Adenocarcinoma: A Systematic Review and Meta-Analysis… Last author DOI 10.1245/s10434-026-20533-3↗
  10. Intranetwork variation in neoadjuvant therapy delivery for borderline resectable and locally advanced pancreatic cancer: a UK multicentre cohort study. Last author DOI 10.1308/rcsann.2026.0023↗
  11. Adjuvant Chemotherapy After Resection of Localized Pancreatic Adenocarcinoma Following Preoperative FOLFIRINOX. Co-author DOI 10.1001/jamaoncol.2024.5917↗
  12. Survival after neoadjuvant and induction FOLFIRINOX versus gemcitabine-nab-paclitaxel in patients with resected localised pancreatic adenocarcinoma: an interna… Co-author DOI 10.1038/s41416-025-03025-1↗
  13. Necessity and Reconstruction Methods of Splenic Vein After Resection of the Portomesenteric Junction During Resections for Pancreatic Cancer. First author DOI 10.3390/curroncol32060316↗
  14. Can preoperative Carbohydrate Antigen 19-9 predict metastatic pancreatic cancer? Results of a systematic review and meta-analysis. Co-author DOI 10.1016/j.hpb.2024.01.017↗
  15. Factors associated with favourable pathological tumour response after neoadjuvant chemotherapy in patients with pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.hpb.2024.09.002↗
  16. Effect of peri-adventitial superior mesenteric artery dissection on margin status during pancreaticoduodenectomy for resectable pancreatic cancer: the DISSECT … Last author DOI 10.1093/bjsopen/zrae075↗
  17. Staging Computed Tomography Parameters Predict the Need for Vein Resection during Pancreaticoduodenectomy in Resectable Pancreatic Ductal Adenocarcinoma. Last author DOI 10.3390/diagnostics14020135↗
  18. Determination of "borderline resectable" pancreatic cancer - A global assessment of 30 shades of grey. Co-author DOI 10.1016/j.hpb.2023.07.883↗
  19. Oncological outcomes after pancreatoduodenectomy for pancreatic ductal adenocarcinoma in octogenarians: case-control study. Last author DOI 10.1093/bjsopen/zrad053↗
  20. Vein Wall Invasion Is a More Reliable Predictor of Oncological Outcomes than Vein-Related Margins after Pancreaticoduodenectomy for Early Stages of Pancreatic … Last author DOI 10.3390/diagnostics13223465↗
  21. Resection of isolated liver oligometastatic disease in pancreatic ductal adenocarcinoma: Is there a survival benefit? A systematic review. Last author DOI 10.4240/wjgs.v15.i7.1512↗
  22. Para-aortic lymph node involvement should not be a contraindication to resection of pancreatic ductal adenocarcinoma. Last author DOI 10.4240/wjgs.v14.i5.429↗
  23. Intention to treat outcomes among patients with pancreatic cancer treated using International Study Group on Pancreatic Surgery recommended pathways for resect… First author DOI 10.1111/ans.16643↗
  24. Surgical Management of Non-Metastatic Pancreatic Cancer in the United Kingdom: Results of a Nationwide Survey on Current Practice. Co-author DOI 10.3389/fonc.2021.791946↗
  25. Recurrence patterns of pancreatic cancer after pancreatoduodenectomy: systematic review and a single-centre retrospective study. Co-author DOI 10.1016/j.hpb.2020.01.005↗
  26. Resection of Replaced Common Hepatic Artery in Locally Advanced Pancreatic Cancer: A Case Report and Analysis of Technical and Oncological Implications. Last author DOI 10.1097/mpa.0000000000001533↗
  27. Treatment Strategies for the Optimal Management of Locally Advanced Pancreatic Adenocarcinoma With Curative Intent: A Systematic Review. Last author DOI 10.1097/mpa.0000000000001694↗

Closest collaborators

The 25 strongest of 33 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Keith John Roberts · 20 shared papers, 2020–2026 · strength 4.10
  2. Robert Peter Sutcliffe · 13 shared papers, 2020–2026 · strength 2.80
  3. David Christopher Bartlett · 11 shared papers, 2022–2026 · strength 2.59
  4. S.S. Raza · 9 shared papers, 2024–2026 · strength 2.29
  5. Shahin Hajibandeh · 5 shared papers, 2024–2026 · strength 1.36
  6. Shahab Hajibandeh · 5 shared papers, 2024–2026 · strength 1.36
  7. Moath Alarabiyat · 4 shared papers, 2025–2026 · strength 1.23
  8. Sarah F. Powell-Brett · 5 shared papers, 2023–2026 · strength 1.17
  9. Lewis A Hall · 4 shared papers, 2024–2026 · strength 0.91
  10. Rupaly Pandé · 5 shared papers, 2020–2024 · strength 0.74
  11. James Michael Halle-Smith · 3 shared papers, 2023–2024 · strength 0.70
  12. Peter Lawrence Zaki Labib · 3 shared papers, 2026 · strength 0.69
  13. Shivan Sivakumar · 2 shared papers, 2026 · strength 0.41
  14. Joseph Anthony Attard · 3 shared papers, 2020–2023 · strength 0.41
  15. Francesco Giovinazzo · 2 shared papers, 2021–2024 · strength 0.35
  16. Manish Singh Ahuja · 2 shared papers, 2022–2023 · strength 0.31
  17. Charlotte Terry · 1 shared paper, 2026 · strength 0.28
  18. Nabeel Merali · 1 shared paper, 2026 · strength 0.28
  19. Adam Enver Frampton · 1 shared paper, 2026 · strength 0.28
  20. Yuk Ting Ma · 2 shared papers, 2020–2021 · strength 0.23
  21. Marit Kalisvaart · 2 shared papers, 2020–2021 · strength 0.21
  22. Francesca Marcon · 2 shared papers, 2020–2021 · strength 0.21
  23. Ricky Harminder Bhogal · 1 shared paper, 2023 · strength 0.14
  24. Bilal A. Al-Sarireh · 1 shared paper, 2023 · strength 0.14
  25. Camila Hidalgo Salinas · 1 shared paper, 2023 · strength 0.14

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.